Beta-Blockers: A Complete Guide
Beta-blockers reduce heart rate and blood pressure by blocking beta-adrenergic receptors. They remain foundational drugs in cardiology, used for hypertension, heart failure, arrhythmias, and post-MI prophylaxis.
What Are Beta-Blockers?
Beta-blockers (beta-adrenergic antagonists) inhibit the action of catecholamines -- epinephrine and norepinephrine -- at beta-adrenergic receptors. Discovered by Sir James Black in 1964, they became one of the most widely prescribed drug classes in cardiovascular medicine.
Receptor Subtypes
There are three main beta-receptor subtypes relevant to pharmacology:
- Beta-1 (B1) -- Predominant in the heart. Blockade reduces heart rate (negative chronotropy), contractility (negative inotropy), and conduction velocity (negative dromotropy).
- Beta-2 (B2) -- Found in bronchial smooth muscle, vascular smooth muscle, and the liver. Blockade can cause bronchoconstriction and mask hypoglycemia.
- Beta-3 (B3) -- Present in adipose tissue, involved in lipolysis and thermogenesis. Less clinically relevant for current beta-blockers.
Classification
Selective (beta-1 preferring): Metoprolol, atenolol, bisoprolol, nebivolol. Preferred in patients with asthma or diabetes because they spare beta-2 receptors at lower doses. Selectivity is dose-dependent and diminishes at higher doses.
Non-selective (beta-1 + beta-2): Propranolol, nadolol, timolol. Propranolol also crosses the blood-brain barrier readily, giving it utility in migraine prophylaxis, performance anxiety, and essential tremor.
Combined alpha/beta blockers: Carvedilol, labetalol. Carvedilol blocks alpha-1, beta-1, and beta-2 receptors and has antioxidant properties. Labetalol is preferred for hypertensive emergencies in pregnancy.
Clinical Uses
- Hypertension -- No longer first-line monotherapy per most guidelines, but valuable in combination and in patients with compelling indications (post-MI, heart failure).
- Heart failure with reduced ejection fraction (HFrEF) -- Bisoprolol, carvedilol, and metoprolol succinate are evidence-based choices that reduce mortality.
- Post-myocardial infarction -- Reduce reinfarction risk and sudden cardiac death.
- Arrhythmias -- Rate control in atrial fibrillation; suppression of catecholamine-driven arrhythmias.
- Other -- Migraine prophylaxis (propranolol), portal hypertension (nadolol, carvedilol), thyrotoxicosis symptom control.
Adverse Effects and Precautions
Common side effects include fatigue, cold extremities, bradycardia, and sexual dysfunction. Abrupt withdrawal can trigger rebound tachycardia and hypertension due to receptor upregulation -- doses should always be tapered.
Contraindications include severe bradycardia, decompensated heart failure, second- or third-degree heart block, and severe bronchospasm. Use caution in diabetes because beta-blockers can mask tachycardia during hypoglycemia.
Key Takeaways
- Beta-blockers reduce mortality in heart failure and post-MI when titrated carefully.
- Selectivity for beta-1 matters most in patients with reactive airway disease or diabetes.
- Never stop beta-blockers abruptly -- always taper over 1-2 weeks.
- Newer agents like nebivolol add nitric oxide-mediated vasodilation with fewer metabolic effects.